SEC Form 10-K filed by Hoth Therapeutics Inc.
Unavailable
Unavailable
Save time and jump to the most important pieces.
In the news release, Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers, issued 12-May-2025 by Hoth Therapeutics, Inc. over PR Newswire, we are advised by the company that the 3rd bullet section, 2nd bullet should read "Significant inhibition of tumor growth". The complete, corrected release follows: Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers HT-KIT dramatically suppresses tumor growth in preclinical models of GIST and systemic mastocytosis. Treatment shows potent downregulation of oncogenic KI
HT-KIT dramatically suppresses tumor growth in preclinical models of GIST and systemic mastocytosis. Treatment shows potent downregulation of oncogenic KIT mutations with no observed systemic toxicity. IND filing expected early 2026, opening pathway to first-in-human trials. Preclinical Milestones: Over 80% reduction in KIT expression in vitro using cancer cell lines harboring activating KIT mutations.Significant inhibition of tumor growth in GIST and mast cell tumor animal models following systemic administration of HT-KIT.No observable off-target toxicity in liver, kidney, or bone marrow, suggesting a favorable safety profile.NEW YORK, May 12, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (
Patent Grant Strengthens Hoth's RNA Therapeutics Pipeline with Broad Claims Covering KIT-Targeted Antisense Oligomers for Oncology and Immunology Applications NEW YORK, April 17, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc.(NASDAQ:HOTH), a clinical-stage biopharmaceutical company developing next-generation RNA-targeted precision therapies, today announced it has been granted a key patent by the Japan Patent Office (JPO), expanding its global intellectual property portfolio in RNA-based cancer therapeutics. The newly issued patent secures broad claims covering antisense oligome
3 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
NEW YORK, Jan. 31, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory Board. While serving on the Board, Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ, an oral therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of Alzheimer's disease (AD) and symptoms associated with AD. Mr. Robb Knie, CEO of Hoth Therapeutics, commented, "Hoth is extremely pleased to welcome Dr. Cir
SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)
8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)
10-Q - Hoth Therapeutics, Inc. (0001711786) (Filer)
8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)